Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology

por Dalakas, Marinos C.
Publicado 2023

Objectivity, practicality, and significance of practice guidelines for the practicing neurologists: What we learnt from consensus criteria in CIDP, Myasthenia Gravis and Inflammato...

por Dalakas, Marinos C.
Publicado 2023

Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost

por Dalakas, Marinos C.
Publicado 2017

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies

por Dalakas, Marinos C.
Publicado 2018

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system

por Dalakas, Marinos C.
Publicado 2018

Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing

por Dalakas, Marinos C.
Publicado 2020

Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications

por Dalakas, Marinos C.
Publicado 2020

Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy

por Dalakas, Marinos C.
Publicado 2021

IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti–B Cell Therapies

por Dalakas, Marinos C.
Publicado 2021

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies

por Dalakas, Marinos C.
Publicado 2022

Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies

por Dalakas, Marinos C.
Publicado 2022

Autoimmune Neurogenic Dysphagia

por Stathopoulos, Panos, Dalakas, Marinos C.
Publicado 2021

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome

por Yi, Jessica, Dalakas, Marinos C.
Publicado 2022

Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies

por Dalakas, Marinos C., Wiendl, Heinz
Publicado 2022

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases

por Stathopoulos, Panos, Dalakas, Marinos C.
Publicado 2022

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors

por Dalakas, Marinos C., Spaeth, Peter J.
Publicado 2021

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder

por Rakocevic, Goran, Alexopoulos, Harry, Dalakas, Marinos C.
Publicado 2019

Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications

por Dalakas, Marinos C., Bitzogli, Kleopatra, Alexopoulos, Harry
Publicado 2021

GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions

por Tsiortou, Popianna, Alexopoulos, Harry, Dalakas, Marinos C.
Publicado 2021

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

por Rakocevic, Goran, Martinez-Outschoorn, Ubaldo, Dalakas, Marinos C.
Publicado 2018